Shares of Isis surged this morning on its updated Phase II trial data of ISIS 301012 in patients with homozygous familial hypercholesterolemia. Three patients with a rare genetic condition that resulted in extremely high cholesterol levels received elevated doses of the drug and saw their cholesterol levels cut in half. The three HoFH patients dosed with 300 mg/week of ISIS 301012 for twelve weeks have now completed treatment. With ISIS 301012, the patients achieved 45%, 50% and 51% additional reductions in LDL-cholesterol beyond that achieved with maximally-tolerated lipid-lowering therapy, with similar reductions in apoB of 45%, 43% and 54%.
Mid-stage cholesterol data sends Isis stock soaring Report